skip to main
|
skip to sidebar
Blog Archives: Nov 2004 - present
Special items: Ovarian Cancer and Us blog best viewed in Firefox
open access: Autologous lysate-pulsed dendritic cell vaccination followed by adoptive transfer of vaccine-primed ex vivo co-stimulated T cells in recurrent ovarian cancer (Coukos et al)
Abstract:
Novel strategies for the therapy of recurrent ovarian cancer are
warranted. We report a study of a combinatorial approach encompassing
dendritic cell (DC)-based autologous whole tumor vaccination and
anti-angiogenesis therapy, followed by the adoptive transfer of
autologous vaccine-primed CD3/CD28-co-stimulate
d lymphocytes. Recurrent
ovarian cancer patients for whom tumor lysate was available from prior
cytoreductive surgery underwent conditioning with intravenous
bevacizumab and oral metronomic cyclophosphamide, sequentially followed
by (1) bevacizumab plus vaccination with DCs pulsed with autologous
tumor cell lysate supernatants, (2) lymphodepletion and (3) transfer of 5
× 109 autologous vaccine-primed T-cells in combination with
the vaccine. Feasibility, safety as well as immunological and clinical
efficacy were evaluated. Six subjects received this vaccination......
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.